Sanofi's Biosimilars Deal With JHL Confirms Growing Trend In China

Sanofi is joining the biosimilars trend to tap into China through a local partnership with Taiwan's JHL Biotech, initially focusing on rituximab, a biosimilar product that has great market potential but strong competition in development by domestic peers.